Table 1 Systematic reviews and meta-analyses evaluating adjunctive corticosteroids for community-acquired pneumonia.
Author, year | Severity and type of pneumonia | Number of studies | number of cases | Conclusion |
|---|---|---|---|---|
Salluh, 200817 | Severe CAP | 3 RCTs and 1 cohort study | 415 | Not recommending CS for severe CAP. |
Siempos, 200818 | CAP with any severity (only studies for severe CAP were found) | 4 RCTs | 189 | Limited data suggested that CS lowers mortality and shortens length of hospital stay for severe CAP. |
Chen, 201119 | Any type of pneumonia. including nosocomial and child pneumonia | 6 RCTs (2 for child, 1 for inhaled CS. | 437 | CS are generally beneficial for pneumonia. Evidence is lacking to make recommendation. |
Nie, 201220 | CAP with any severity. | 9 RCTs | 1001 | CS is not recommended for CAP in general. However, it is possible that CS lower mortality from severe CAP and that CS > 6 d may be more beneficial than CS ≤ 5 d. |
Cheng, 201321 | Severe CAP | 4 RCTs | 264 | Limited evidence suggests that CS lowers mortality from severe CAP. |
Shafiq, 201322 | CAP requiring admission. | 8 RCTs | 1119 | CS shortens length of hospital stay. CS does not lower mortality. |
Current study | CAP requiring admission. | 10 RCTs | 1780 | CS shortens length of hospital stay for CAP. CS shortens length to clinical stability for CAP. CS lowers mortality for CAP in intensive care unit. CS > 6 d is not more beneficial than CS ≤ 5 d. |
